Mary E Lambert

US Patent:

7638283, Dec 29, 2009

Filed:

May 16, 2005

Appl. No.:

11/130566

Inventors:

Grant A. Krafft - Glenview IL, US
William L. Klein - Winnetka IL, US
Brett A. Chromy - Evanston IL, US
Mary P. Lambert - Glenview IL, US
Caleb E. Finch - Altadena CA, US
Todd Morgan - Manhattan Beach CA, US
Pat Wals - Los Angeles CA, US
Irina Rozovsky - Pasadena CA, US
Ann Barlow - Evanston IL, US

Assignee:

Northwestern University - Evanston IL
University of Southern California - Los Angeles CA

International Classification:

G01N 33/53
A61K 38/00
A61K 51/00

US Classification:

435 71, 514 2, 424 169

Abstract:

The invention described in this disclosure involves a new composition of matter, amyloid beta-derived dementing ligands (ADDL's). ADDLs consist of amyloid β peptide assembled into soluble globular non-fibrillar oligomeric structures that are capable of activating specific cellular processes. The invention further encompasses methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. The invention further encompasses assay methods and inhibitor molecules for cellular signaling molecules activated by ADDLs. Also described are molecules that block proteins that promote the formation of ADDLs.

US Patent:

8507206, Aug 13, 2013

Filed:

Jul 5, 2005

Appl. No.:

11/571532

Inventors:

Mary P Lambert - Glenview IL, US
Pauline T. Velasco - Wilmette IL, US
Lei Chang - Westmont IL, US
Kirsten L. Viola - Chicago IL, US
Sara J. Fernandez - Chicago IL, US
Pascale N. Lacor - Chicago IL, US
Daliya Khuon - Chicago IL, US
Yuesong Gong - Evanston IL, US
William L. Klein - Winnetka IL, US
Grant A. Krafft - Glenview IL, US

Assignee:

Northwestern University - Evanston IL
Acumen Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

G01N 33/53

US Classification:

435 71, 5303881

Abstract:

Disclosed herein are antibodies that bind with high specificity to soluble oligomers of amyloid β (Abeta) and methods of employing those antibodies. The antibodies are able to distinguish between Alzheimer's Disease (AD) and control human brain extracts. The antibodies identify endogenous Abeta oligomers in AD brain slices and also bind to Abeta oligomers on cultured hippocampal cells. The antibodies neutralize endogenous Abeta oligomers and Abeta oligomers produced in solution.

US Patent:

20030068316, Apr 10, 2003

Filed:

Jun 11, 2002

Appl. No.:

10/166856

Inventors:

William Klein - Winnetka IL, US
Grant Krafft - Glenview IL, US
Mary Lambert - Glenview IL, US
Kirsten Viola - Chicago IL, US
Brett Chromy - Pleasanton CA, US
Yue Gong - Evanston IL, US
Lei Chang - Evanston IL, US
Todd Morgan - Los Angeles CA, US
Irina Rozofsky - Pasadena CA, US
Caleb Finch - Altadena CA, US

International Classification:

A61K039/395

US Classification:

424/130100

Abstract:

The invention herein comprises antibodies that bind to amyloid beta-derived diffusible ligands (ADDLs). ADDLs comprise amyloid protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.

US Patent:

20060178302, Aug 10, 2006

Filed:

Apr 6, 2005

Appl. No.:

11/100212

Inventors:

Grant Krafft - Glenview IL, US
William Klein - Winnetka IL, US
Brett Chromy - Evanston IL, US
Mary Lambert - Glenview IL, US
Caleb Finch - Altadena CA, US
Todd Morgan - Manhattan Beach CA, US
Pat Wals - Los Angeles CA, US
Irina Rozovsky - Pasadena CA, US
Ann Barlow - Evanston IL, US

International Classification:

A61K 38/17
C07K 14/47

US Classification:

514012000, 530350000

Abstract:

The invention provides amyloid beta-derived dementing ligands (ADDLs) that comprise amyloid β protein assembled into globular non-fibrillar oligomeric structures capable of activating specific cellular processes. The invention also provides methods for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDLs, and modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.

US Patent:

20070048312, Mar 1, 2007

Filed:

Jul 31, 2006

Appl. No.:

11/496149

Inventors:

William Klein - Winetka IL, US
Grant Krafft - Glenview IL, US
Mary Lambert - Glenview IL, US
Kirsten Viola - Chicago IL, US
Brett Chromy - Danville CA, US
Lei Chang - Westmont IL, US

International Classification:

A61K 39/395

US Classification:

424145100, 424146100

Abstract:

The invention herein comprises antibodies that bind to amyloid beta-derived diffusible ligands (ADDLs). ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes.

US Patent:

20070213512, Sep 13, 2007

Filed:

Mar 15, 2007

Appl. No.:

11/686570

Inventors:

Grant Krafft - Glenview IL, US
William Klein - Winnetka IL, US
Kirsten Viola - Chicago IL, US
Mary Lambert - Glenview IL, US
Todd Pray - San Mateo CA, US
Ray Lowe - San Francisco CA, US

International Classification:

C07K 14/00

US Classification:

530395000

Abstract:

The present invention provides amyloid β peptide assemblies composed of at least three amyloid β peptide subunits, wherein at least one of the amyloid β peptide subunits is an amyloid β peptide analog. The invention further relates to metal complexes of amyloid β peptide assemblies and the use of amyloid β peptide assemblies as vaccines and in the identification of agents that modulate assembly of the amyloid β peptide subunits.

US Patent:

20080176252, Jul 24, 2008

Filed:

Jun 1, 2005

Appl. No.:

11/142869

Inventors:

Grant A. Krafft - Glenview IL, US
William L. Klein - Winnetka IL, US
David W. Summa - Hillsborough CA, US
Brett A. Chromy - Danville CA, US
Lei Chang - Evanston IL, US
Mary P. Lambert - Glenview IL, US
Kirsten L. Viola - Chicago IL, US
Yuesong Gong - Evanston IL, US

International Classification:

G01N 33/567
G01N 33/566

US Classification:

435 721, 436501

Abstract:

The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.

US Patent:

20080306074, Dec 11, 2008

Filed:

May 16, 2005

Appl. No.:

11/569122

Inventors:

Pascale N. Lacor - Chicago IL, US
Kirsten L. Viola - Chicago IL, US
Mary P. Lambert - Glenview IL, US
Lei Chang - Westmont IL, US
Pauline T. Velasco - Wilmette IL, US
Eileen H. Bigio - Riverside IL, US
Maria C. Buniel - Cleveland OH, US
Sara J. Fernandez - Chicago IL, US
Jasna Jerecic - San Francisco CA, US
Susan Catalano - Hayward CA, US
Todd Pray - San Mateo CA, US
Ray Lowe - San Francisco CA, US
Grant A. Krafft - Glenview IL, US
William L. Klein - Winnetka IL, US

International Classification:

A61K 31/498
G01N 33/567
A61P 25/28

US Classification:

514249, 435 721

Abstract:

Disclosed and claimed herein are compositions comprising ADDL receptors, related compositions, and related methods. ADDL receptors are typically, but perhaps not exclusively, localized at the post-synaptic density (PSD) of neuronal cells. Related compositions include, but are not limited to, compounds that affect, positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Related methods include, but are not limited to, procedures to screen for compounds that affect, either positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Other related methods include, but are not limited to, prevention and treatment of ADDL-related diseases, such as Alzheimer's disease, mild cognitive impairment, Down's syndrome, and the like, using compositions that inhibit, block, or otherwise interfere with ADDL binding to one or more receptors localized at the post-synaptic density of neuronal cells.